German insurers oppose EU Biotech Act

German social insurers are advocating for the removal of a patent extension clause in the EU Biotech Act, which they argue extends pharmaceutical monopolies. This push is expected to lead to a heated debate among lawmakers, as the current rules impact drug prices and access to medicines. The outcome will have significant implications for the biotech industry and healthcare systems across the EU.

Summarized from the sources above. Read the originals for the full story.